Mar 01, 2024
BioMarin Scheduled to Participate in March Investor Conferences
Feb 22, 2024
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
Feb 06, 2024
BioMarin to Present ROCTAVIAN(TM) (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
Jan 03, 2024
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
Feb 24, 2021
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
Feb 18, 2021
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
Jan 26, 2021
BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
Jan 05, 2021
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
Dec 21, 2020
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Dec 01, 2020
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
Nov 17, 2020
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
Nov 12, 2020
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
Nov 05, 2020
BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
Nov 04, 2020
BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12:30pm ET
Oct 22, 2020
BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET
Oct 02, 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
Sep 29, 2020
BioMarin to Participate in Upcoming Virtual Investor Conference
Sep 24, 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy
Sep 15, 2020
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
Sep 08, 2020
BioMarin to Participate in Two Upcoming Virtual Investor Conferences